All Stories

  1. C-Ring Structure-Dependent Redox Properties of Flavonoids Regulate the Expression of Bioactivity
  2. Estimation of the metabolic stability of omipalisib in human liver microsomes employing an ultra-fast UPLC-MS/MS approach: in silico screening for structural alarms and metabolic lability
  3. Quantification of buparlisib in human liver microsomes employing an ultra-fast, sensitive UPLC-MS/MS method: in vitro and in silico metabolic stability evalua...
  4. Green Ultra‐Fast UPLC–MS/MS Method for Enasidenib Quantification in HLMs Matrix With the Metabolic Stability Assessment: In Silico Study for Structural Alerts, ADME Characteristics and Metaboslic Lability
  5. Mitigating testicular dysfunction: Metformin’s role in combating valproic acid-induced damage in rats
  6. Evaluation of Niraparib Metabolic Stability in Human Liver Microsomes Using Ultrafast UPLC‐MS/MS Technique: In Silico Screening for Structural Alerts Related to the Metabolic Lability and In Silico DEREK Toxicity
  7. Cellular cAMP Content and Mitochondrial Profile Define Different Subtypes of Ovarian Cancer Cells
  8. Ultra-fast eco-friendly UHPLC–MS/MS methodology for the quantification of ASP3026 in human liver microsomes: Evaluation of metabolic stability via in silico software and in vitro metabolic incubation
  9. Evaluation of Anlotinib Metabolic Stability in HLMs Matrix Applying Ultra‐Fast UPLC–MS/MS Approach: Greenness Assessment With In Silico Testing for Structural Alarms Related to the Metabolic Lability and DEREK Toxicity
  10. Ultra‐Fast Green UPLC‐MS/MS Method for the Quantification of Cediranib in the Human Liver Microsome Matrix: In Vitro and In Silico Metabolic Stability Assessment
  11. Synthesis of a novel dual-functional Ti₃C₂ MXene-based composite for sustainable photocatalytic CO₂ conversion and pollutant degradation: Characterization and optimization of process parameters
  12. An ultra-fast validated green UPLC-MS/MS approach for the evaluation of zanubrutinib in vitro metabolic stability in human liver microsomes: Screening for in silico metabolic lability, ADME parameters, and DEREK toxic alerts
  13. Ziziphus spina-christi alleviates paracetamol-induced hepatorenal toxicity in rats through in vivo and computational approaches
  14. Generative artificial intelligence, integrative bioinformatics, and single-cell analysis reveal Alzheimer’s genetic and immune landscape
  15. Recent SARS-CoV-2 evolution trajectories indicate the emergence of Omicron's several subvariants and the current rise of KP.3.1.1 and XEC
  16. Deciphering the structural and dynamic effects of SHP2-E76 mutations: mechanistic insights into oncogenic activation
  17. Boosting photocatalytic H2O2 production and non-biodegradable ofloxacin removal via a novel Ti3C2 MXene nanosheet-supported BiVO4/InVO4 Z-scheme heterojunction: Optimization and mechanism insights
  18. Engineering a novel BiVO4-CuFe2O4@MXene heterojunction with boosted photocatalytic activity: Visible-light-driven enrofloxacin degradation from polluted water and H2 production
  19. A Computational Quest for Finding Novel Drug Targets against Mycobacterium tuberculosis
  20. Activin-A urine levels correlate with radiological patterns in preterm infants complicated by intraventricular hemorrhage
  21. Cigarette Smoke and Heated Tobacco Product Exhibit Distinct Biochemical Pathways of Microglial Activation Under Hypoxia-Reoxygenation
  22. Validated and green UPLC-MS/MS method for belumosudil quantification in human liver microsomes: Application to in vitro metabolic stability assessment
  23. Phylogenetic analyses of the spread of Clade I MPOX in African and non-African nations
  24. Ejaculatory abstinence duration impacts semen parameters: Insights from a retrospective analysis in male infertility on 23,527 analyses
  25. Changes in adrenomedullin in bronchoalveolar lavage fluid with chorioamnionitis in a sheep-based model
  26. Sensory Characteristics and Impact of Flavanol-Rich Grape and Blueberry Extract on Blood Flow Velocity and Oxidative Stress
  27. An ultra-fast validated green UPLC-MS/MS method for the quantification of osimertinib in human liver microsomes: Screening for ADME parameters and in vitro metabolic stability
  28. An ultra-fast UPLC-MS/MS approach for the quantification of baricitinib in the HLM matrix: greenness assessment with application to in vitro and in silico metabolic stability studies
  29. An Ultrafast UPLC‐MS/MS Approach for Determining the In Vitro Metabolic Stability of Duvelisib in the HLMs: In Silico Screening for Metabolic Lability, ADME Features, and DEREK Alerts
  30. Quercetin, Isoquercitrin, and Quercetin‐3‐Rutinoside: Understanding the Pharmacological, Organoleptic, ADME Properties, Human Health Toxicity, Ecological Risk, and Cosmetic Risk of Using Integrative Bioinformatics
  31. A comparative analysis of the impact of repeated administration of flavan 3-ol on brown, subcutaneous, and visceral adipose tissue
  32. Assessment of the metabolic stability of avapritinib in human liver microsomes using a fast and green UPLC-MS/MS method: screening for structural alarms associated with metabolic lability and in silico tox...
  33. Determination of veliparib metabolic stability in the human liver microsomes using a hydrophilic interaction UPLC-MS/MS quantitative method: greenness assessment with an in silico study for ADME, DEREK ala...
  34. Development and validation of a quick and sensitive UPLC-MS/MS method for measuring ensartinib in HLMs: investigation of structural alerts associated with metabolic lability and in silico toxicity
  35. Validated green ultra-fast UPLC-MS/MS method for the quantification of fedratinib in an HLM matrix: application to in vitro and in silico metabolic stability ...
  36. Integrative approaches to m6A and m5C RNA modifications in autism spectrum disorder revealing potential causal variants
  37. An immunohistochemical evaluation of fast twitch muscle formation induced by repeated administration of flavan 3‐ols in mice
  38. An Ultra-Fast Validated Green UPLC-MS/MS Approach for Assessing Revumenib in Human Liver Microsomes: In Vitro Absorption, Distribution, Metabolism, and Excretion and Metabolic Stability Evaluation
  39. Heavy Metal Nanoparticle Detection in Human and Formula Milk
  40. Change in Nfkb/Nrf2/Bax Levels by High Monomeric Polyphenols Berries Extract (HMPBE) in Acute and Chronic Secondary Brain Damage
  41. An Ultra-Fast Green UHPLC-MS/MS Method for Assessing the In Vitro Metabolic Stability of Dovitinib: In Silico Study for Absorption, Distribution, Metabolism, Excretion, Metabolic Lability, and DEREK Alerts
  42. Redox Modulation of Meniere Disease by Coriolus versicolor Treatment, a Nutritional Mushroom Approach with Neuroprotective Potential
  43. Assessment of the in vitro metabolic stability of CEP-37440, a selective FAK/ALK inhibitor, in HLMs using fast UPLC–MS/MS method: in silico metabolic lability and DEREK alerts screening
  44. Unraveling the enigma: Probing the unconventional binding site and binding mechanism of entrectinib with human serum albumin through spectroscopic, molecular docking, and dynamic simulation analyses
  45. Capillary blood parameters are gestational age, birthweight, delivery mode and gender dependent in healthy preterm and term infants
  46. Presepsin in Human Milk Is Delivery Mode and Gender Dependent
  47. An ultra‐fast green ultra‐high‐performance liquid chromatography‐tandem mass spectrometry method for estimating the in vitro metabolic stability of zotizalkib in human liver microsomes
  48. An ultra‐fast ultra‐high‐performance liquid chromatography‐tandem mass spectrometry method for estimating the in vitro metabolic stability of palbociclib in human liver microsomes: In silico study for metabolic lability, absorption, distribution, metab...
  49. Transgenerational hormesis in healthy aging and antiaging medicine from bench to clinics: Role of food components
  50. Characterization of the in vitro metabolic profile of nazartinib in HLMs using UPLC-MS/MS method: In silico metabolic lability and DEREK structural alerts screening using StarDrop software
  51. Ultra-fast UPLC–MS/MS approach for estimating X-376 in human liver microsomes: Evaluation of metabolic stability via in silico software and in vitro analysis
  52. Effects of long and short ejaculatory abstinence on sperm parameters: a meta-analysis of randomized-controlled trials
  53. CYP7B1 as a Biomarker for Prostate Cancer Risk and Progression: Metabolic and Oncogenic Signatures (Diagnostic Immunohistochemistry Analysis by Tissue Microarray in Prostate Cancer Patients—Diamond Study)
  54. Phase angle at bioelectric impedance analysis is associated with detrimental sperm quality in idiopathic male infertility: a preliminary clinical study
  55. Sensory Properties, Redox Characteristics, and Impact on the Hemodynamics of the Flavanol-Rich Fraction Originated Grape and Blueberry
  56. Microglia and glioblastoma heterocellular interplay sustains tumour growth and proliferation as an off‐target effect of radiotherapy
  57. REDOXOMICS IN AGEING AND NEURODEGENERATIVE DISORDERS: FROM BENCH TO CLINICS
  58. Autophagy machinery plays an essential role in traumatic brain injury-induced apoptosis and its related behavioral abnormalities in mice: focus on Boswellia Sacra gum resin
  59. Ion Trap LC/MS reveals the generation of reactive intermediates in acalabrutinib metabolism: phase I metabolic profiling and bioactivation pathways elucidation
  60. Frankincense: A neuronutrient to approach Parkinson’s disease treatment
  61. Corrigendum to “Frankincense: A neuronutrient to approach Parkinson’s disease treatment”
  62. Ponatinib: A comprehensive drug profile
  63. Polyphenols in Inner Ear Neurobiology, Health and Disease: From Bench to Clinics
  64. Hormesis defines the limits of lifespan
  65. An Ultrafast UPLC–MS/MS Method for Characterizing the In Vitro Metabolic Stability of Acalabrutinib
  66. A Sensitive, Green, and Fast LC–MS/MS Analytical Method for the Quantification of Ribociclib: Evaluation of the Metabolic Stability in HLMs
  67. A Fast LC-MS/MS Methodology for Estimating Savolitinib in Human Liver Microsomes: Assessment of Metabolic Stability Using In Vitro Metabolic Incubation and In Silico Software Analysis
  68. Binding of Novobiocin Paves the Way for Inhibition of DEAH-box Helicase 8
  69. Synthesis, Molecular Docking, c-Met Inhibitions of 2,2,2-Trichloroethylidene- cyclohexane-1, 3-dione Derivatives Together with their Application as Target SARS-CoV-2 main Protease (Mpro) and as Potential anti-COVID-19
  70. Reactive intermediates formation and bioactivation pathways of spebrutinib revealed by LC-MS/MS: In vitro and in silico metabolic study
  71. Investigation of Fenebrutinib Metabolism and Bioactivation Using MS3 Methodology in Ion Trap LC/MS
  72. Development of a Fast and Sensitive UPLC–MS/MS Analytical Methodology for Fenebrutinib Estimation in Human Liver Microsomes: In Vitro and In Silico Metabolic Stability Evaluation
  73. An UPLC–ESI–MS/MS Bioanalytical Methodology for the Quantification of Gilteritinib in Human Liver Microsomes: Application to In Vitro and In Silico Metabolic Stability Estimation
  74. A Rapid and Sensitive UPLC-MS/MS Method for Quantifying Capmatinib in Human Liver Microsomes: Evaluation of Metabolic Stability by In Silico and In Vitro Analysis
  75. MemophenolTM Prevents Amyloid-β Deposition and Attenuates Inflammation and Oxidative Stress in the Brain of an Alzheimer’s Disease Rat
  76. Mechanism of Action of Natural Compounds in Peripheral Multiorgan Dysfunction and Hippocampal Neuroinflammation Induced by Sepsis
  77. Spectroscopic and computational investigation of the interaction between the new anticancer agent enasidenib and human serum albumin
  78. Estimation of zorifertinib metabolic stability in human liver microsomes using LC–MS/MS
  79. A validated LC-MS/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes
  80. Development of novel univariate and multivariate validated chemometric methods for the analysis of dasatinib, sorafenib, and vandetanib in pure form, dosage forms and biological fluids
  81. Spectroscopic, molecular docking and dynamic simulation studies of binding between the new anticancer agent olmutinib and human serum albumin
  82. Simple and efficient spectroscopic-based univariate sequential methods for simultaneous quantitative analysis of vandetanib, dasatinib, and sorafenib in pharmaceutical preparations and biological fluids
  83. LC–MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation
  84. Synthesis of Novel Halogenated Heterocyclic compounds and their uses as Target SARS-CoV-2 main Protease (Mpro) and Potential Anti-Covid-19
  85. <p>Characterization of Stable and Reactive Metabolites of the Anticancer Drug, Ensartinib, in Human Liver Microsomes Using LC-MS/MS: An in silico and Practical Bioactivation Approach</p>
  86. Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation
  87. <p>LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay</p>
  88. Biophysical Insight into the Interaction of Human Lysozyme with Anticancer Drug Anastrozole: A Multitechnique Approach
  89. Corrigendum to “Investigating the site selective binding of busulfan to human serum albumin: Biophysical and molecular docking approaches” [Int. J. Biol. Macromol. 107 (2018) 1414–1421]
  90. Corrigendum to “Deciphering the enhanced inhibitory, disaggregating and cytoprotective potential of promethazine towards amyloid fibrillation.” [Int. J. Biol. Macromol. 106 (2018) 851–863]
  91. Biophysical insight into the interaction of levocabastine with human serum albumin: spectroscopy and molecular docking approach
  92. <p>Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC–MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies</p>
  93. Phase I metabolic profiling and unexpected reactive metabolites in human liver microsome incubations of X-376 using LC-MS/MS: bioactivation pathway elucidation andin silicotoxicity studies of its metabolites
  94. Spectroscopic and molecular docking studies reveal binding characteristics of nazartinib (EGF816) to human serum albumin
  95. Azilsartan medoxomil
  96. Emtricitabine
  97. Detection and characterization of olmutinib reactive metabolites by LC–MS/MS: Elucidation of bioactivation pathways
  98. Potent Activity of a Novel Vanadyl (IV)-Vitamin D3 Complex Against Streptozotocin-Induced Diabetes in Rats: Synthesis, Characterization and Biological Assessments
  99. Structural, spectroscopic, Hirshfeld surface and charge distribution analysis of 3-(1H-imidazole-1-yl)-1-phenylpropan-1-ol complemented by molecular docking predictions: An integrated experimental and computational approach
  100. Antiproliferative activity and possible mechanism of action of certain 5-methoxyindole tethered C-5 functionalized isatins
  101. Liquid chromatography–tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites
  102. A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation
  103. Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability
  104. Novel BTK inhibitor acalabrutinib (ACP-196) tightly binds to site I of the human serum albumin as observed by spectroscopic and computational studies
  105. Reactive intermediates and bioactivation pathways characterization of avitinib by LC–MS/MS: In vitro metabolic investigation
  106. A simple liquid chromatography-tandem mass spectrometry method to accurately determine the novel third-generation EGFR-TKI naquotinib with its applicability to metabolic stability assessment
  107. Reactive intermediates in copanlisib metabolism identified by LC-MS/MS: phase I metabolic profiling
  108. Molecular interactions of AL3818 (anlotinib) to human serum albumin as revealed by spectroscopic and molecular docking studies
  109. Spectroscopic and molecular docking studies of the binding of the angiotensin II receptor blockers (ARBs) azilsartan, eprosartan and olmesartan to bovine serum albumin
  110. Synthesis, Spectroscopic Identification and Molecular Docking of Certain N-(2-{[2-(1H-Indol-2-ylcarbonyl)hydrazinyl](oxo)acetyl}phenyl)acetamides and N-[2-(2-{[2-(Acetylamino)phenyl](oxo)acetyl}hydrazinyl)-2-oxoethyl]-1H-indole-2-carboxamides: New Anti...
  111. Interaction of catecholamine precursor l-Dopa with lysozyme: A biophysical insight
  112. Investigating the site selective binding of busulfan to human serum albumin: Biophysical and molecular docking approaches
  113. Unraveling the binding characteristics of the anti-HIV agents abacavir, efavirenz and emtricitabine to bovine serum albumin using spectroscopic and molecular simulation approaches
  114. Deciphering the enhanced inhibitory, disaggregating and cytoprotective potential of promethazine towards amyloid fibrillation
  115. Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS: in vitro phase I metabolic investigation
  116. Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma
  117. Probing the interaction of cephalosporin antibiotic–ceftazidime with human serum albumin: A biophysical investigation
  118. Biophysical and In Silico Studies of the Interaction between the Anti-Viral Agents Acyclovir and Penciclovir, and Human Serum Albumin
  119. Cationic surfactant mediated fibrillogenesis in bovine liver catalase: a biophysical approach
  120. Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in vitro pharmacological profiling
  121. Exploring the interaction forces involved in the binding of the multiple myeloma drug lenalidomide to bovine serum albumin
  122. Synthesis and Biophysical Insights into the Binding of a Potent Anti-Proliferative Non-symmetric Bis-isatin Derivative with Bovine Serum Albumin: Spectroscopic and Molecular Docking Approaches
  123. Anti-Parkinsonian L-Dopa can also act as anti-systemic amyloidosis—A mechanistic exploration
  124. Ascorbic acid inhibits human insulin aggregation and protects against amyloid induced cytotoxicity
  125. Biophysical insight reveals tannic acid as amyloid inducer and conformation transformer from amorphous to amyloid aggregates in Concanavalin A (ConA)
  126. A multitechnique approach to probe the interaction of a therapeutic tyrosine kinase inhibitor nintedanib and bovine serum albumin
  127. Liquid chromatographic-tandem mass spectrometric assay for simultaneous quantitation of tofacitinib, cabozantinib and afatinib in human plasma and urine
  128. Fluorescence spectroscopic and molecular docking studies of the binding interaction between the new anaplastic lymphoma kinase inhibitor crizotinib and bovine serum albumin
  129. Polyols (Glycerol and Ethylene glycol) mediated amorphous aggregate inhibition and secondary structure restoration of metalloproteinase-conalbumin (ovotransferrin)
  130. A biophysical and computational study unraveling the molecular interaction mechanism of a new Janus kinase inhibitor Tofacitinib with bovine serum albumin
  131. Mechanisms of protein misfolding: Novel therapeutic approaches to protein-misfolding diseases
  132. Solution conformation and flexibility of capsular polysaccharides from Neisseria meningitidis and glycoconjugates with the tetanus toxoid protein
  133. Correction: A Comprehensive Spectroscopic and Computational Investigation to Probe the Interaction of Antineoplastic Drug Nordihydroguaiaretic Acid with Serum Albumins
  134. An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma
  135. Liquid chromatographic-mass spectrometric method for determination of drug content uniformity of two commonly used dermatology medications in a split-tablet dosage form
  136. A Comprehensive Spectroscopic and Computational Investigation to Probe the Interaction of Antineoplastic Drug Nordihydroguaiaretic Acid with Serum Albumins
  137. Interaction of the recently approved anticancer drug nintedanib with human acute phase reactant α 1-acid glycoprotein
  138. A novel method to determine new potent angiotensin inhibitor, azilsartan, in human plasma via micelle-enhanced spectrofluorimetry using cremophor RH 40
  139. Binding of Janus kinase inhibitor tofacitinib with human serum albumin: multi-technique approach
  140. Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches
  141. ChemInform Abstract: Structure of Amyloid Oligomers and Their Mechanisms of Toxicities: Targeting Amyloid Oligomers Using Novel Therapeutic Approaches
  142. Interplay of multiple interaction forces: Binding of tyrosine kinase inhibitor nintedanib with human serum albumin
  143. Interaction of new kinase inhibitors cabozantinib and tofacitinib with human serum alpha-1 acid glycoprotein. A comprehensive spectroscopic and molecular Docking approach
  144. A glycoconjugate of Haemophilus influenzae Type b capsular polysaccharide with tetanus toxoid protein: hydrodynamic properties mainly influenced by the carbohydrate
  145. A highly efficient and sensitive LC-MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study
  146. A Spectroscopic Approach to Investigate the Molecular Interactions between the Newly Approved Irreversible ErbB blocker "Afatinib" and Bovine Serum Albumin
  147. Simultaneous quantitative analysis of olmesartan, amlodipine and hydrochlorothiazide in their combined dosage form utilizing classical and alternating least squares based chemometric methods
  148. Effect of galactose on acid induced molten globule state of Soybean Agglutinin: Biophysical approach
  149. Experimental and Theoretical Studies of the Vibrational and Electronic Properties of (2E)-2-[3-(1H-imidazol-1-yl)-1-phenyl-propylidene]-N-phenylhydrazinecarboxamide: An Anticonvulsant Agent
  150. Erratum to: Biophysical Interactions of Novel Oleic Acid Conjugate and its Anticancer Potential in HeLa Cells
  151. Biophysical Interactions of Novel Oleic Acid Conjugate and its Anticancer Potential in HeLa Cells
  152. A new method to determine the new C-Met inhibitor “Cabozantinib” in dosage form and human plasma via micelle-enhanced spectrofluorimetry
  153. Spectrofluorimetric study of finasteride and bovine serum albumin interaction and its application for quantitative determination of finasteride in tablet dosage form
  154. Nanosuspension: An Emerging Trend for Bioavailability Enhancement of Etodolac
  155. Insight into the Interaction between the HIV-1 Integrase Inhibitor Elvitegravir and Bovine Serum Albumin: A Spectroscopic Study
  156. Characterization of Capsular Polysaccharides and Their Glycoconjugates by Hydrodynamic Methods
  157. Micellar Enhanced Spectrofluorimetric Method for the Determination of Ponatinib in Human Plasma and Urine via Cremophor RH 40 as Sensing Agent
  158. HPLC method with monolithic column for simultaneous determination of irbesartan and hydrochlorothiazide in tablets
  159. A Validated HPLC-DAD Method for Simultaneous Determination of Etodolac and Pantoprazole in Rat Plasma
  160. Pseudo-MS3Approach Using Electrospray Mass Spectrometry (ESI-MS/MS) to Characterize Certain (2E)-2-[3-(1H-Imidazol-1-yl)-1-phenylpropylidene]hydrazinecarboxamide Derivatives
  161. A Stability-Indicating HPLC-DAD Method for Determination of Stiripentol: Development, Validation, Kinetics, Structure Elucidation and Application to Commercial Dosage Form
  162. Multistage Fragmentation of Ion Trap Mass Spectrometry System and Pseudo-MS3of Triple Quadrupole Mass Spectrometry Characterize Certain (E)-3-(Dimethylamino)-1-arylprop-2-en-1-ones: A Comparative Study
  163. Characterization and Anticancer Potential of Newly Synthesized Propofol Conjugates
  164. Induced in-source fragmentation pattern of certain novel (1Z,2E)-N-(aryl)propanehydrazonoyl chlorides by electrospray mass spectrometry (ESI-MS/MS)
  165. Comparative ANNs with Different Input Layers and GA-PLS Study for Simultaneous Spectrofluorimetric Determination of Melatonin and Pyridoxine HCl in the Presence of Melatonin’s Main Impurity
  166. High Throughput Quantitative Bioanalytical LC/MS/MS Determination of Gemifloxacin in Human Urine
  167. An asymmetric and slightly dimerized structure for the tetanus toxoid protein used in glycoconjugate vaccines
  168. Solution properties of capsular polysaccharides from Streptococcus pneumoniae
  169. Extended Fujita approach to the molecular weight distribution of polysaccharides and other polymeric systems
  170. On the hydrodynamic analysis of conformation in mixed biopolymer systems
  171. Molecular Weight Distribution Evaluation of Polysaccharides and Glycoconjugates Using Analytical Ultracentrifugation
  172. An analytical ultracentrifuge study on ternary mixtures of konjac glucomannan supplemented with sodium alginate and xanthan gum
  173. A novel global hydrodynamic analysis of the molecular flexibility of the dietary fibre polysaccharide konjac glucomannan